<DOC>
	<DOCNO>NCT01554163</DOCNO>
	<brief_summary>The main purpose study establish etoricoxib 30 mg safe inferior celecoxib 200 mg treatment sign symptom osteoarthritis Korean patient . Given efficacy etoricoxib vs. placebo treatment osteoarthritis establish , prescription drug , celecoxib , available treatment pain associate osteoarthritis Korea , would inappropriate subject patient flare osteoarthritic pain placebo treatment 12 week , thus study design active-comparator study .</brief_summary>
	<brief_title>Safety Efficacy Etoricoxib 30 mg Versus Celecoxib 200 mg Korean Participants With Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Patient least 40 year age Clinical diagnosis osteoarthritis knee great 6 month base clinical radiographic criterion Female patient childbearing potential must negative pregnancy test prior study enrollment must agree remain abstinent , use barrier , intramuscular , implanted contraceptive Visit 1 28 day last dose study medication . Patient American Rheumatism Association ( ARA ) functional Class I , II , III Patient willing limit alcohol intake 2 less drink per day study followup period Patient willing avoid unaccustomed physical activity duration study followup period With exception osteoarthritis , patient judge good general health base medical history , physical exam , routine laboratory test Patient able read , understand complete study questionnaire , include question require visual analog scale ( VAS ) response Patient provide write informed consent trial For prior nonsteroidal antiinflammatory drug ( NSAID ) user , patient history positive therapeutic benefit NSAIDs take NSAID prior study enrollment therapeutic dose level prior study enrollment ( Visit 1 ) For prior NSAID user , patient assessment Pain Walking Flat Surface ( WOMAC Section A , Question1 ) Visit 1 ( prestudy ) less 80 mm ( 100 mm VAS ) For prior NSAID user , prior randomization , follow discontinuation NSAIDs washout period specify patient must satisfy follow 3 flare criterion : Minimum 40 mm patient report Pain Walking Flat Surface ( WOMAC Section A , Question 1 ) ; Increase 15 mm patient report Pain Walking Flat Surface ( WOMAC Section A , Question 1 ) compare prestudy baseline record Visit 1 ; A worsening Investigator Global Assessment Disease Status least 1 category 5 category scale compare Visit 1 recording For prior acetaminophen/paracetamol user , patient take acetaminophen/paracetamol regular basis prior study enrollment ( Visit 1 ) use NSAIDs treatment osteoarthritis knee For prior acetominophen/paracetamol user , Visits 1 2 , patient must satisfy follow 3 criterion : Minimum 40 mm patient report Pain Walking Flat Surface ( WOMAC Section A , Question 1 ) ; Investigator Global Assessment Disease Status fair , poor , poor ; Minimum 40 mm Patient Global Assessment Disease Status ( 100 mm VAS ) Patient concurrent medical/arthritic disease could confound interfere evaluation efficacy Patient legally incompetent ( e.g. , minor mentally incapacitate ) , active psychosis , significant emotional problem time study view investigator sufficient interfere conduct study Patient history gastric biliary surgery ( include gastric bypass surgery ) , small intestine surgery cause clinical malabsorption Patient allergic , history significant clinical laboratory adverse experience associate etoricoxib celecoxib constituent Patient allergic acetaminophen/paracetamol , hypersensitivity ( e.g. , bronchoconstriction association nasal polyp ) aspirin NSAIDs Patient estimate glomerular filtration rate le equal 30 ml/min Patient Class IIIV congestive heart failure Patient establish ischemic heart disease , cerebrovascular disease , peripheral vascular disease Patient uncontrolled hypertension diastolic exclusionary limit &gt; 90 mm Hg systolic exclusionary limit &gt; 140 mm Hg Patient moderate severe hepatic insufficiency define Child Pugh score &gt; 6 Patient history neoplastic disease Patient history illness , opinion investigator , might confound result study pose additional risk patient Patient , time signing informed consent , user recreational illicit drug recent history ( within last 5 year ) drug alcohol abuse dependence Patients consider morbidly obese body mass index ( BMI ) ≥ 35 kg/m^2 Patient new use ( within 2 week Visit 1 entire duration study followup period ) physical medicine modality involve study joint , include limited : physical therapy , chiropractic intervention , acupuncture , Transcutaneous Electrical Nerve Stimulator ( TENS ) , ultrasound Patient expect undergo surgery involve study joint course study Patients take oral contraceptive Patients use intraarticular steroid hyaluronic acid injection study knee immunosuppressant medication within 3 month Visit 1 Patients use intravenous , intramuscular , oral corticosteroid , intraarticular steroid hyaluronic acid injection joint study joint within 1 month Visit 1 Patients use topical systemic analgesic medication within 3 day Visit 1 throughout duration study Patients use nonstudy NSAID cyclooxygenase 2 ( COX2 ) specific inhibitor study treatment period , exception lowdose aspirin ( ≤ 325 mg/day ) Patients receive Chinese traditional arthritis treatment within 1 week Visit 1 Patients clinically significant abnormality Visit 1 clinical examination laboratory safety test . Serum transaminases ≤ 150 % upper limit normal Patients currently participate participate study investigational drug device within 4 week sign informed consent Patients active peptic ulcer history inflammatory bowel disease Patients personal family history inherit acquire bleed Patients pregnant breastfeeding , expect conceive within project duration study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Celecoxib</keyword>
	<keyword>Etoricoxib</keyword>
</DOC>